Program
D-methadone
Also written as “REL-1017” and “REL1017 (esmethadone HCI) (active drug)”.
Its studies are mostly in Depressive Disorder, Major · Neuralgia, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Relmada Therapeutics | 60 open or running | phase 3since Dec 7, 2020 | Feb 3, 2017 | none ahead |
| Levomecor | 20 open or running | phase 3since Apr 19, 2021 | Apr 19, 2021 | none ahead |
| MGGM | 10 open or running | phase 3since Dec 13, 2024 | Dec 13, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 3, 2017First study: phase 2 study in Depressive Disorder, MajorNew to Relmada TherapeuticsRelmada Therapeutics · NCT03051256 · 62 enrolled · United States
- Aug 10, 20182 phase 1 studies in NeuralgiaRelmada Therapeutics · NCT03638869, NCT03637361
- Dec 7, 2020Phase 3 study in Depressive Disorder, MajorRelmada Therapeutics · NCT04688164 · 227 enrolled · United States
- Apr 19, 2021Phase 3 study in Depressive Disorder, MajorRelmada Therapeutics · NCT04855760 · 627 enrolled · United States
- Apr 19, 2021Levomecor's first study: phase 3 study in Depressive Disorder, MajorNew to LevomecorLevomecor · NCT04855747 · 236 enrolled · United States
- Oct 4, 2021Phase 3 study in Depressive Disorder, MajorRelmada Therapeutics · NCT05081167 · 232 enrolled · United States
- Aug 21, 2023Phase 3 study in Depressive Disorder, MajorLevomecor · NCT06011577 · 27 enrolled · United States
- Dec 13, 2024MGGM's first study: phase 3 study in Depressive Disorder, MajorNew to MGGMMGGM · NCT06735079 · Italy, Switzerland
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06735079Depressive Disorder, Major · Italy, Switzerland | 3 | Withdrawn | MGGM | Dec 1, 2026 | 0 |
| NCT06011577Depressive Disorder, Major · United States | 3 | Terminated | Levomecor | Dec 19, 2024 | 27 |
| NCT05081167Depressive Disorder, Major · United States | 3 | Completed | Relmada Therapeutics | Sep 13, 2022 | 232 |
| NCT04855760Depressive Disorder, Major · United States | 3 | Completed | Relmada Therapeutics | Jul 27, 2023 | 627 |
| NCT04855747Depressive Disorder, Major · United States | 3 | Terminated | Levomecor | Dec 31, 2024 | 236 |
| NCT04688164Depressive Disorder, Major · United States | 3 | Completed | Relmada Therapeutics | Nov 1, 2022 | 227 |
| NCT03638869Neuralgia | 1 | Completed | Relmada Therapeutics | Nov 16, 2015 | 24 |
| NCT03637361Neuralgia | 1 | Completed | Relmada Therapeutics | Jun 2, 2015 | 42 |
| NCT03051256Depressive Disorder, Major · United States | 2 | Completed | Relmada Therapeutics | Jul 30, 2019 | 62 |
How it is read
Names in the registry
- “REL-1017”, 8 entries
- “REL1017 (esmethadone HCI) (active drug)”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 7 studies
- Neuralgia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.